DR info

Clinical trials : 23 / Drugs : 15 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 33

Leber hereditary optic neuropathy and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability

ID	Diseases (Sorted by drug repositionability)
302	Leber hereditary optic neuropathy
326	Osteopetrosis
13	Multiple sclerosis/Neuromyelitis optica
6	Parkinson disease
299	Cystic fibrosis
20	Adrenoleukodystrophy
2	Amyotrophic lateral sclerosis
62	Paroxysmal nocturnal hemoglobinuria
63	Idiopathic thrombocytopenic purpura
36	Epidermolysis bullosa
39	Toxic epidermal necrolysis
160	Congenital ichthyosis
19	Lysosomal storage disease
46	Malignant rheumatoid arthritis
49	Systemic lupus erythematosus
51	Scleroderma
60	Aplastic anemia
61	Autoimmune hemolytic anemia
65	Primary immunodeficiency
66	IgA nephropathy
85	Idiopathic interstitial pneumonia
96	Crohn disease
158	Tuberous sclerosis
222	Primary nephrotic syndrome
283	Acquired pure red cell aplasia
285	Fanconi anemia
53	Sjogren syndrome
26	HTLV-1-associated myelopathy
28	Systemic amyloidosis
162	Pemphigoid
228	Bronchiolitis obliterans
90	Retinitis pigmentosa
113	Muscular dystrophy
227	Osler disease
93	Primary biliary cholangitis
38	Stevens-Johnson syndrome
50	Dermatomyositis
56	Behcet disease
107	Juvenile idiopathic arthritis
97	Ulcerative colitis
58	Hypertrophic cardiomyopathy
164	Oculocutaneous albinism
40	Takayasu arteritis
41	Giant cell arteritis
151	Rasmussen encephalitis
226	Interstitial cystitis with Hunners ulcer
269	Pyogenic arthritis
42	Polyarteritis nodosa
45	Eosinophilic granulomatosis with Polyangiitis
55	Relapsing polychondritis
95	Autoimmune hepatitis
284	Diamond-Blackfan anemia
11	Myasthenia gravis
224	Purpura nephritis
274	Osteogenesis Imperfecta
286	Hereditary sideroblastic anemia
64	Thrombotic thrombocytopenic purpura
234	Peroxisomal disease (except Adrenoleukodystrophy)